



MicroRNA expression profile in the spinal cord injured rat neurogenic bladder by next-generation sequencing

Zhenhua Shang, Tongwen Ou, Jianjun Xu, Hao Yan, Bo Cui, Qi Wang, Jiangtao Wu, Chunsong Jia, Xin Cui, Jin Li

Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, China

Contributions: (I) Conception and design: Z Shang, T Ou; (II) Administrative support: Z Shang, J Xu, H Yan, B Cui; (III) Provision of study materials or patients: Z Shang, J Xu, J Wu, Q Wang; (IV) Collection and assembly of data: Z Shang, T Ou, C Jia; (V) Data analysis and interpretation: Z Shang, T Ou, X Cui, J Li; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Tongwen Ou. Department of Urology, Xuanwu Hospital Capital Medical University, No. 45 Changchun Street, Xuanwu District, Beijing 100053, China. Email: outongwen1967@126.com.

Background: An increasing amount of evidence has indicated that microRNAs (miRs) are involved in most biological conditions, including the neurogenic bladder (NB). However, to our knowledge, no studies have investigated these miR expressions in spinal cord-injured (SCI) rat NB. The goal of the study was to explore the miR expression profile in the SCI rat NB by next-generation sequencing (NGS).

Methods: Female Wistar rats underwent spinal cord transection at T9–10 and were randomly divided into the SCI-1, SCI-2 and SCI-3 groups (n=5 for each group) whose bladder tissues were collected 1, 2, and 4 weeks after transection, respectively. The normal rats were used as the normal control (NC) group. MiRs microarray assays were used to detect the differentially expressed miRs between the groups by NGS, which was then verified by quantitative real-time polymerase chain reaction (qRT-PCR). Those significantly differently expressed miRs were analyzed with Gene Ontology categories and Kyoto Encyclopedia of Genes and Genomes bioinformatical analyses.

Results: Compared with the NC group, 96, 28 and 51 miRs were downregulated in the rats' bladder in the SCI-1, SCI-2, and SCI-3 groups, respectively, and 133, 49, and 76 miRs were upregulated respectively. Specifically, miR-21-5p was the most significantly upregulated miR in all SCI groups. Also, 121 miRs (SCI-1 *vs.* SCI-2), 98 miRs (SCI-1 *vs.* SCI-3), and 26 miRs (SCI-2 *vs.* SCI-3) were of significantly different expression. Furthermore, a large set of genes implicated in essential signaling pathways were targeted by these miRs, including PI3K-Akt, MAPK, Rap1, and cGMP-PKG signaling pathways, along with the tight junction and metabolic pathways.

Conclusions: This is the first demonstration of differentially expressed miRs, which may potentially serve as new molecular targets in the SCI rat NB.

Keywords: MicroRNAs (miRs); neurogenic bladder (NB); spinal cord injury; rats; next-generation sequencing (NGS)

Submitted Jan 12, 2020. Accepted for publication Jun 22, 2020.

doi: 10.21037/tau-20-415

View this article at: <http://dx.doi.org/10.21037/tau-20-415>

Introduction

It has been estimated that 250,000 to 500,000 people worldwide are suffering from spinal cord injury and approximately 81% of these patients experience different

levels of neurogenic bladder (NB) which is one of the leading causes of their morbidity (1,2). Specifically, detrusor overactivity and detrusor-sphincter dyssynergia are typical NB urodynamic findings, and are diagnosed in 95% and 68% of spinal cord-injured (SCI) patients, respectively (3).

These involuntary bladder contractions could result in urinary incontinence episodes during the storage phase, inefficient urine voiding, and high residual volume during urine voiding, potentially leading to upper urinary tract damage and substantially impacting the health-related quality of life (4). At the same time, the currently available treatment options are not satisfactory.

The exact mechanisms of NB secondary in spinal cord injury have not yet been identified. It is postulated that C fibers mediated new spinal reflex circuits and neurotrophic hormones like nerve growth factor participate in NB after spinal cord injury (5). In recent years, an increased amount of evidence has indicated that microRNAs (miRs) are essential regulators of most physiological and pathological events, which might also include the potential pathophysiology and treatment outcomes of NB. MiRs are non-coding RNAs, approximately 19–23 nucleotides (nt) in length. They participate in epigenetic post-transcriptional control of protein-coding gene expression primarily by reversible translational repression or mRNA destabilization/degradation and thereby inhibit protein synthesis (6).

Recently, Chermansky *et al.* reported that the elevated expression of miR-221 and miR-125b in detrusor overactivity in the bladder tissue of patients may predict their high risk for undergoing urinary retention following intradetrusor injection of onabotulinumtoxin-A (6). In addition, the combination of upregulated miR-98-5p and downregulated miR-139-5p in the plasma of patients' overactive bladder (OAB) was found to be a useful biomarker for OAB. However, no correlation was determined between the levels of miRs and OAB symptom score (7). Meanwhile, the above research only concentrated on finding the expression patterns of miRNA particularly in OAB patients. To our knowledge, no studies have comprehensively investigated miR expressions in the SCI rat NB.

Therefore, this study aimed to explore the miR expression profile in the SCI rat bladder by next-generation sequencing (NGS), which may yield molecular targets for NB. Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) bioinformatical analyses were also performed to investigate the functions of these miRs. We present the following article in accordance with the ARRIVE reporting checklist (available at <http://dx.doi.org/10.21037/tau-20-415>).

Methods

Ethical approval

All experimental procedures were implemented in

compliance with the National Institute of Health Guidelines for the Care and Use of Laboratory Animals (2) and approved by the Institutional Animal Care and Use Committee of Xuanwu Hospital Capital Medical University (No. 20190128).

SCI rat model

Adult female Wistar rats weighing 200–250 g (Beijing Charles River Laboratories Animal Technology Co., Ltd., Beijing, China) were used in this study, as their urethras are shorter and more conducive to bladder evacuation via abdominal compression. The animals were maintained at 20–26 °C and 30–70% relative humidity under a 12-h light/dark cycle with ad libitum access to food and water. The spinal cord was transected at the T9–10 in rats. Under 3% enflurane inhalation in the rats, Th10 laminectomy was performed, and the dura was sharply transected. The spinal cord was completely severed at T10, and Gelfoam (Ethicon) was placed between the cut ends to aid in hemostasis and to prevent the cut ends from healing. The muscle layer and skin were separately sutured. The rats received ampicillin sodium (100 mg/kg intramuscularly) for 5 days after operation. Bladders were emptied 3 times daily by abdominal compression until reflex voiding returned, and once a day afterward. The normal rats were used as the normal control (NC) group.

Bladder collection

Before bladder collection, 15 female Wistar rats that underwent spinal cord transection at T9–10 were randomly divided into SCI-1, SCI-2, and SCI-3 groups (n=5 for each group), and their bladder tissues were collected 1, 2, and 4 weeks after spinal cord transection, respectively. The rats were anesthetized with 3% enflurane inhalation, and a midline laparotomy was performed in the lower abdomen to expose the bladder. Each bladder was surgically removed at the level of the bladder neck and longitudinally cut into halves on ice. The bladder tissues were then stored in liquid nitrogen.

MiRs microarray procedures

Three samples of each group and 3 replicates of each tissue were used for RNA sequencing. Libraries were constructed using the NEBNext® Multiplex Small RNA Library Prep Set for Illumina (Set 2; New England BioLabs, Inc.,

Ipswich, MA, USA). Briefly, total RNA was isolated by using Trizol (Invitrogen; Thermo Fisher Scientific, Inc., USA). The quantity and integrity of RNA yield were assessed by using the Qubit[®]2.0 (Life Technologies, USA) and Agilent 2200 TapeStation (Agilent Technologies, USA) separately. Enriched fragments were sequenced by HiSeq 2500 Sequencing System (Illumina Inc., San Diego, CA, USA) with single-end 50 bp at Ribobio Co. Ltd (Ribobio, China).

Data processing and bioinformatic analysis

The raw reads were filtered to obtain clean reads by removing those with an adaptor sequence or those with a percentage of unknown bases more than 10%, low-quality reads, and smaller than 17 nt reads by FASTQC. The clean reads obtained were mapped to reference genome by Burrows-Wheeler Aligner (BWA) software. miRDeep2 software was used to identify the known mature miRNA based on miRBase21 (www.miRBase.org) and predict novel miRNA. Databases of Rfam12.1 (www.rfam.xfam.org) and pirnabank (www.pirnabank.ibab.ac.in) were used to identify ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA) and PIWI-interacting RNA (piRNA) by Basic Local Alignment Search Tool (BLAST). The miRNA expression was counted and normalized by reads per million (RPM) values [PRM = (number of reads mapping to miRNA/number of reads in clean data) × 10⁶]. Differential expression between samples was calculated by DESeq2 algorithm according to the criteria of log₂ |fold change| >1 and P < 0.05. TargetScan, miRDB, miRTarBase, and miRWalk were used to predict the genes targeted by selected miRNA. KOBAS was used for further GO and KEGG pathway analyses.

Quantitative real-time polymerase chain reaction (qRT-PCR)

qRT-PCR analysis was performed to verify the accuracy of the microarray assays. MiR expressions were determined by the CFX Connect[™] Real-Time PCR detection system (Bio-Rad Laboratories, CA, USA) in triplicate and calculated using the 2^{-ΔΔCt} method. U6 was used as an internal reference for miRs. Primers for qRT-PCR were provided by Bulge-Loop miRNA qRT-PCR Primer Sets (Guangzhou RiboBio Co., Ltd., Guangzhou, China). Total RNA was extracted from samples of the bladder by using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., USA). cDNAs were synthesized from 2 μg of total RNA using a mixture

of Oligo-dT and random primers or specific primers with M-MLV reverse transcriptase (Promega Corporation, USA). The following thermocycling conditions were used: 95 °C for 1 minute, followed by 40 cycles at 95 °C for 10 seconds, 60 °C for 20 seconds, and 70 °C for 10 seconds.

Statistical analysis

Differential expression analysis of miRs obtained from NGS was performed by the DESeq2 (v. 1.16.1), which was an algorithm to examine differences between groups by using a generalized linear model and assuming a negative binomial distribution of RNA-Seq reads. Statistically, differences in the levels of miRs verified by qRT-PCR between groups were determined by analysis of variance (ANOVA) using SPSS 21.0 (SPSS, Inc., Chicago, IL, USA). Data are presented as mean ± standard deviation (SD). The differentially expressed miRNAs were identified using the following thresholds: P < 0.05; log₂ |fold change| > 1. A value of P < 0.05 was considered to indicate a statistically significant difference.

Results

Identification of differentially expressed miRs between SCI and NC groups

Compared with the NC group, 96, 28 and 51 miRs were significantly downregulated in the bladders of the SCI-1, SCI-2, and SCI-3 groups, respectively, and 133, 49 and 76 miRs were significantly upregulated in the rat bladders of SCI-1, SCI-2 and SCI-3 groups, respectively (*Tables 1-3*). Specifically, miR-21-5p was the most significantly upregulated miR in all the SCI groups. Moreover, 206 new miRs were identified in the bladder and are shown in *Table S1*.

Identification of differentially expressed miRs between SCI groups

Compared with the SCI-1 group, 81 and 65 miRs were significantly downregulated in the rat bladders of the SCI-2 and SCI-3 groups, respectively, and 40 and 33 miRs were significantly upregulated in the rat bladders of the SCI-2 and SCI-3 groups respectively (*Tables 4,5*). Compared with the SCI-2 group, 5 miRs were significantly downregulated, and 21 miRs were significantly upregulated in the rat bladders of the SCI-3 groups (*Table 6*).

Table 1 Ninety-six significantly down-regulated and 133 significantly up-regulated miRNAs in SCI-1 group compared to NC group

miRNA	log ₂ -ratio (SCI-1/NC)	P value
miR-139-5p	-3.102182882	1.75E-56
miR-21-5p	2.221163332	1.35E-49
miR-466c-5p	3.184432599	2.95E-42
miR-125a-5p	-1.829219179	1.80E-41
miR-149-5p	-2.143417515	2.49E-37
miR-1-3p	-2.194065038	1.02E-34
miR-181a-5p	-1.623090527	3.15E-33
miR-145-5p	-2.367867781	4.84E-33
miR-411-5p	2.866397294	4.01E-32
miR-132-3p	2.337233687	1.42E-30
miR-298-5p	3.050317374	1.67E-30
miR-328a-3p	-1.91132018	7.08E-30
miR-129-5p	-2.684218688	1.19E-29
miR-133a-3p	-2.639745931	3.86E-29
miR-382-3p	3.083780543	1.81E-28
miR-495	3.246664284	1.49E-27
miR-132-5p	2.637582812	3.47E-26
miR-379-5p	2.713173134	3.87E-26
miR-212-3p	3.166034219	1.23E-25
miR-379-3p	2.891056501	1.52E-25
miR-411-3p	3.093952173	2.15E-25
miR-139-3p	-2.428682251	4.64E-25
miR-29c-5p	-2.259756176	4.76E-25
miR-1193-3p	3.095183493	7.12E-25
miR-376b-3p	3.811300461	3.84E-23
miR-212-5p	2.698225438	1.46E-22
miR-15b-3p	2.48316802	3.42E-22
miR-320-3p	-1.678142165	3.77E-22
miR-494-3p	2.782278241	4.84E-22
miR-540-3p	2.538638666	1.25E-21
miR-493-5p	2.588627944	3.42E-21
miR-434-5p	2.665719473	5.01E-21
miR-134-5p	2.399485438	5.71E-21
miR-431	2.280672634	1.87E-20

Table 1 (continued)**Table 1** (continued)

miRNA	log ₂ -ratio (SCI-1/NC)	P value
miR-341	2.091476704	3.20E-20
miR-99b-5p	-1.332158911	6.20E-20
miR-133b-3p	-2.39189828	5.72E-19
miR-204-5p	-1.959297741	5.85E-19
miR-129-1-3p	-2.892021806	8.06E-19
let-7d-3p	-1.636823106	9.13E-19
miR-29b-5p	-2.447544506	9.97E-19
miR-410-3p	2.213844944	1.11E-18
miR-299a-3p	2.584887153	1.24E-18
miR-338-5p	-2.041548097	1.87E-18
miR-466b-5p	2.878992417	2.83E-18
miR-1b	-1.75345764	9.93E-18
miR-299b-3p	2.572487155	1.16E-17
miR-296-3p	3.946209334	1.40E-17
miR-127-5p	2.144357263	3.13E-17
miR-181d-5p	-1.481396568	3.28E-17
miR-370-3p	1.940524375	4.39E-17
miR-30c-2-3p	-1.46199406	5.88E-17
miR-409a-3p	2.003956093	4.11E-16
miR-130b-5p	1.90853073	4.59E-16
miR-184	2.346878698	4.61E-16
miR-543-3p	1.906948855	7.94E-16
miR-300-3p	2.067638501	8.03E-16
miR-29a-3p	-1.037912307	9.18E-16
miR-409a-5p	2.179408619	1.30E-15
miR-1249	-1.889683111	1.63E-15
miR-23b-3p	-1.555750442	2.12E-15
miR-380-3p	3.30194013	3.54E-15
miR-143-5p	-1.477749401	3.95E-15
miR-127-3p	1.460866685	6.67E-15
miR-150-5p	-1.682559818	4.99E-14
miR-541-5p	2.132434591	5.02E-14
miR-221-3p	1.369736139	5.67E-14
miR-337-5p	1.679642486	5.92E-14
miR-452-5p	2.848340092	9.00E-14

Table 1 (continued)

Table 1 (continued)

miRNA	log ₂ -ratio (SCI-1/NC)	P value
miR-125b-5p	-1.083888826	1.05E-13
let-7e-3p	-1.450696119	1.16E-13
miR-30a-3p	-1.155344661	1.59E-13
miR-504	-2.292273523	1.77E-13
miR-223-5p	2.302263875	1.88E-13
miR-378b	-1.209495332	2.91E-13
miR-503-5p	1.430411192	3.19E-13
miR-708-5p	-1.719135844	3.87E-13
miR-211-5p	-1.863725451	4.51E-13
miR-31a-5p	1.460585107	4.80E-13
miR-378a-5p	-1.269112031	5.68E-13
let-7e-5p	-1.133920645	7.24E-13
miR-496-3p	2.541231703	7.40E-13
miR-378a-3p	-1.212208456	9.26E-13
miR-140-5p	1.346569902	1.70E-12
miR-330-3p	-1.575317256	2.24E-12
miR-155-5p	1.491246802	4.30E-12
miR-223-3p	1.787455625	4.88E-12
miR-322-5p	1.679814718	8.14E-12
miR-770-3p	1.980950727	2.36E-11
miR-342-3p	-1.567011952	4.32E-11
miR-676	-1.569928685	4.43E-11
miR-218a-5p	1.331073023	4.76E-11
miR-450a-5p	1.295604623	1.03E-10
miR-505-3p	-1.336336399	1.12E-10
miR-9a-5p	-1.316114776	1.25E-10
miR-423-5p	-1.037698356	1.45E-10
miR-142-5p	1.720418902	1.56E-10
miR-146b-5p	1.479442337	1.91E-10
miR-450b-5p	1.220783652	2.94E-10
miR-542-3p	1.667710786	4.17E-10
miR-331-3p	-1.23153033	5.48E-10
miR-493-3p	1.888123357	7.97E-10
miR-193a-5p	-1.306363196	8.38E-10

Table 1 (continued)

Table 1 (continued)

miRNA	log ₂ -ratio (SCI-1/NC)	P value
miR-181b-5p	-1.029122766	8.74E-10
miR-26b-3p	-1.620736939	9.29E-10
miR-433-3p	1.333581542	1.31E-09
miR-31a-3p	2.320944268	1.62E-09
miR-758-3p	2.375835876	2.13E-09
miR-29c-3p	-1.334293219	2.86E-09
miR-361-3p	-1.067846562	5.43E-09
miR-511-3p	1.768513538	5.83E-09
miR-374-5p	1.057767481	7.12E-09
miR-363-3p	1.167009367	9.19E-09
miR-466b-4-3p	3.573146084	1.41E-08
miR-466b-2-3p	3.573146084	1.41E-08
miR-17-5p	1.35661569	2.26E-08
miR-434-3p	1.112430116	2.51E-08
miR-330-5p	-1.272071423	3.05E-08
miR-126a-3p	1.105891785	3.19E-08
miR-193b-3p	-1.193427185	4.13E-08
miR-485-3p	1.309238138	4.16E-08
miR-652-3p	-1.151824972	4.25E-08
miR-664-2-5p	-1.325200111	4.49E-08
miR-181c-5p	-1.344033479	5.11E-08
miR-124-3p	-2.736550476	5.53E-08
miR-296-5p	1.94671836	5.92E-08
miR-664-3p	-1.280718524	7.10E-08
miR-369-5p	1.704897781	8.05E-08
let-7i-3p	-1.144553333	1.01E-07
miR-30c-1-3p	-1.141885436	1.41E-07
miR-376a-5p	2.898910594	1.45E-07
miR-136-3p	2.276879909	2.03E-07
miR-147	4.722615042	2.07E-07
miR-324-5p	-1.474568556	2.09E-07
miR-383-5p	-1.367148471	3.87E-07
miR-369-3p	2.419026089	4.14E-07
miR-1306-5p	-1.143077487	4.41E-07

Table 1 (continued)

Table 1 (continued)

miRNA	log ₂ -ratio (SCI-1/NC)	P value
miR-665	2.72800571	6.66E-07
miR-365-3p	-1.154939824	7.90E-07
miR-1843a-3p	-1.186555516	8.82E-07
miR-466b-3p	2.014219539	1.01E-06
miR-210-3p	-1.243918488	1.04E-06
miR-133a-5p	-1.421989127	1.15E-06
miR-24-1-5p	-1.168682039	1.39E-06
miR-382-5p	1.129487387	1.93E-06
let-7b-3p	-1.115343686	2.07E-06
miR-326-3p	-1.333250513	2.08E-06
miR-346	-2.187914853	2.27E-06
miR-582-3p	1.155652793	2.62E-06
miR-29b-3p	-1.175745009	3.11E-06
miR-380-5p	2.227842964	3.16E-06
miR-146b-3p	1.133080107	3.17E-06
miR-129-2-3p	-2.216258422	3.54E-06
miR-99a-3p	-1.898295287	5.38E-06
miR-3577	-1.450639165	6.42E-06
miR-154-5p	1.303208005	6.67E-06
miR-206-3p	-1.425103365	7.05E-06
miR-338-3p	-1.139524526	7.92E-06
miR-299a-5p	1.493976295	9.67E-06
miR-7a-1-3p	1.448137132	1.26E-05
miR-3559-5p	1.157007276	1.27E-05
miR-217-5p	-1.060663628	1.86E-05
miR-34c-5p	1.165838023	1.93E-05
miR-34b-5p	1.35654223	3.37E-05
miR-708-3p	-1.298912776	3.62E-05
miR-329-3p	1.011931442	4.03E-05
miR-324-3p	-1.056232828	4.14E-05
miR-1247-3p	1.439598936	4.23E-05
miR-204-3p	-1.603099354	5.53E-05
miR-3594-3p	-2.097600786	5.83E-05
miR-3102	-1.301393539	6.19E-05

Table 1 (continued)

Table 1 (continued)

miRNA	log ₂ -ratio (SCI-1/NC)	P value
miR-675-3p	5.376720886	6.25E-05
miR-298-3p	1.666250663	9.25E-05
miR-3064-5p	-1.386971792	0.0001146
miR-135b-5p	-1.018638112	0.00011753
miR-6329	1.253243538	0.00012762
miR-130b-3p	1.906869385	0.00014886
miR-3099	-2.879178527	0.00016084
miR-138-1-3p	-1.694585122	0.00017551
miR-362-5p	1.107395298	0.00018552
miR-376b-5p	1.388725246	0.00019653
miR-20b-5p	2.411053913	0.00035965
miR-673-3p	1.645167515	0.00041933
miR-203b-3p	2.187699694	0.0004772
miR-146a-3p	3.056395912	0.00052588
miR-20a-5p	1.074404903	0.00054571
miR-21-3p	1.28424385	0.00086862
miR-667-5p	2.138578479	0.00087156
miR-582-5p	1.726650312	0.00087391
miR-377-3p	4.707555166	0.00097947

GO and KEGG analyses of signaling pathways and genes targeted by these differentially expressed miRs

A large set of essential signaling pathways were targeted by these miRs, including PI3K-Akt, MAPK, Rap1, and cGMP-PKG signaling pathways, along with the tight junction, metabolic pathways, regulation of actin cytoskeleton and pathways in cancer, as shown in *Figure 1*. Meanwhile, *Figure 2* shows the genes targeted by these miRs. For example, Smad7 and Smad5 were targeted by miR-21-5p, while nfat5 was targeted by miR-146a-5p, miR-139-5p, and miR-132-3p.

Validation of miR expression by qRT-PCR

The levels of 5 differentially expressed miRs, including miR-139-5p, miR-21-5p, miR-149-5p, miR-146a-5p, and miR-134-5p, were assessed by qRT-PCR to verify the results of microarray assays. As shown in *Figure 3*, miR-139-5p was significantly downregulated in all SCI

Table 2 Twenty-eight significantly down-regulated and 49 significantly up-regulated miRNAs in SCI-2 group compared to NC group

miRNA	log ₂ -ratio (SCI-2/NC)	P value
miR-21-5p	1.342771	1.08E-18
miR-31a-5p	1.894352	1.32E-18
miR-139-5p	-1.67075	1.89E-17
miR-155-5p	1.834116	2.43E-16
miR-149-5p	-1.51517	2.42E-15
miR-129-5p	-1.95962	2.04E-14
miR-204-5p	-1.72873	5.57E-13
miR-223-3p	2.086425	2.68E-12
miR-429	1.296582	1.94E-11
miR-140-5p	1.388503	2.14E-11
miR-338-5p	-1.49331	2.11E-10
miR-322-5p	1.54202	2.15E-10
miR-15b-3p	1.873105	1.94E-09
miR-9a-5p	-1.15968	1.70E-08
miR-211-5p	-1.64161	1.96E-08
miR-708-3p	-1.98602	2.24E-08
miR-132-3p	1.44845	2.79E-08
miR-139-3p	-1.12477	3.02E-08
miR-212-5p	1.434302	7.44E-08
miR-221-3p	1.018423	8.46E-08
miR-200a-3p	1.206934	1.92E-07
miR-676	-1.37977	2.31E-07
miR-203a-3p	1.011467	3.33E-07
miR-223-5p	2.167995	3.66E-07
miR-17-5p	1.444012	4.51E-07
miR-362-5p	1.420823	6.40E-07
miR-129-1-3p	-1.60183	7.43E-07
miR-15b-5p	1.187088	8.77E-07
miR-31a-3p	1.962596	2.48E-06
miR-204-3p	-2.44611	2.67E-06
miR-212-3p	1.678392	3.93E-06
miR-466c-5p	1.529295	4.77E-06
miR-338-3p	-1.34871	5.35E-06

Table 2 (continued)**Table 2** (continued)

miRNA	log ₂ -ratio (SCI-2/NC)	P value
miR-339-5p	1.132377	6.99E-06
miR-370-3p	-1.31691	7.92E-06
miR-221-5p	1.025674	1.26E-05
miR-147	4.128422	1.76E-05
miR-20a-5p	1.408173	2.99E-05
miR-99a-5p	-1.0657	3.32E-05
miR-15a-5p	1.228399	6.76E-05
miR-106b-5p	1.022472	7.36E-05
miR-9a-3p	-2.00532	7.53E-05
miR-10a-3p	1.013045	8.64E-05
miR-19b-3p	1.63836	9.43E-05
miR-148a-3p	-1.03707	0.000161853
miR-543-3p	-1.24524	0.000319661
miR-466b-4-3p	2.586543	0.000373783
miR-466b-2-3p	2.586543	0.000373783
miR-132-5p	1.00103	0.000412543
miR-466b-5p	1.46694	0.000446337
miR-142-3p	1.364244	0.00051408
miR-20b-5p	2.501238	0.000667041
miR-203b-3p	2.212203	0.00093856
miR-298-5p	1.403063	0.000959402
miR-142-5p	1.045109	0.000990114

groups compared to the NC group, and miR-21-5p was significantly upregulated in all SCI groups. Furthermore, miR-149-5p was also significantly downregulated in all SCI groups. Nevertheless, miR-146a-5p was significantly upregulated by 5.48-, 2.51-, and 3.46-fold in the SCI-3 group compared to the NC, SCI-1, and SCI-2 groups, respectively, and miR-134-5p was significantly upregulated in the SCI-1 group compared to the NC, SCI-2, and SCI-3 groups.

Discussion

To the best of our knowledge, this study is the first to comprehensively investigate the miRs expression profile in SCI rat NB. The present results showed that

Table 3 Fifty-one significantly down-regulated and 76 significantly up-regulated miRNAs in SCI-3 group compared to NC group

miRNA	log ₂ -ratio (SCI-3/NC)	P value
miR-21-5p	2.37181238	2.11E-65
miR-450a-5p	2.62226041	1.17E-33
miR-322-5p	3.03263678	1.01E-31
miR-503-5p	2.96141352	1.05E-30
miR-450b-5p	2.65797646	7.88E-30
miR-140-5p	1.94388628	6.09E-22
miR-149-5p	-1.8875642	6.82E-22
miR-139-5p	-1.6688496	9.62E-18
miR-129-5p	-2.1236755	4.93E-17
miR-146a-5p	1.7800553	5.72E-17
miR-155-5p	2.26176078	1.39E-16
miR-542-3p	2.28731257	2.49E-15
miR-147	7.14321921	4.84E-15
miR-504	-2.3276966	1.18E-14
miR-429	2.24780895	4.41E-14
miR-338-5p	-1.8158385	1.21E-13
miR-466c-5p	2.42073356	1.53E-13
miR-223-5p	2.95912087	2.09E-13
miR-212-5p	2.18225192	3.08E-13
miR-142-3p	2.61231457	3.54E-13
let-7d-5p	-1.0453551	5.21E-13
miR-181a-5p	-1.0653858	1.34E-12
miR-466b-5p	2.69953044	1.56E-12
miR-132-3p	1.83951489	1.83E-12
miR-328a-3p	-1.2027914	2.29E-11
miR-455-3p	-1.5686893	4.56E-11
miR-200a-3p	1.76934063	4.78E-11
miR-200b-3p	1.62826789	5.17E-11
miR-139-3p	-1.4391414	9.75E-11
let-7d-3p	-1.3420112	1.73E-10
miR-363-3p	1.97278183	2.44E-10
miR-223-3p	1.98995205	2.85E-10
miR-129-1-3p	-2.2960898	1.11E-09
miR-132-5p	1.60294222	2.62E-09

Table 3 (continued)**Table 3** (continued)

miRNA	log ₂ -ratio (SCI-3/NC)	P value
miR-221-5p	1.6469837	1.39E-08
miR-130b-5p	2.24560005	1.47E-08
miR-22-3p	1.10175038	6.16E-08
miR-125a-5p	-1.0591798	1.18E-07
miR-532-5p	1.18702295	2.29E-07
miR-146b-3p	1.9820625	6.25E-07
miR-15b-3p	1.64451454	7.80E-07
miR-362-5p	1.64335274	8.72E-07
miR-142-5p	3.57927795	9.02E-07
miR-146a-3p	4.28699097	1.23E-06
miR-181a-2-3p	-1.4024575	2.42E-06
miR-676	-1.1301808	3.31E-06
miR-34c-5p	1.50066546	3.51E-06
miR-126a-5p	1.03740906	3.70E-06
miR-19b-3p	1.74623161	3.81E-06
let-7e-3p	-1.0694482	4.36E-06
miR-505-3p	-1.0887262	6.73E-06
miR-146b-5p	2.87650384	7.74E-06
miR-31a-3p	1.93258402	9.86E-06
miR-295-3p	4.83073688	2.07E-05
miR-1306-5p	-1.232282	2.72E-05
miR-20b-5p	2.97228599	2.94E-05
miR-200a-5p	1.31731223	3.69E-05
miR-17-2-3p	2.49633491	3.76E-05
miR-124-3p	-2.3386931	3.80E-05
miR-221-3p	1.02916013	4.24E-05
miR-3102	-1.7001201	4.80E-05
miR-292-5p	4.64055069	5.34E-05
miR-375-3p	-1.2552555	5.36E-05
miR-193a-5p	-1.073083	5.49E-05
miR-26b-3p	-1.2414321	7.03E-05
miR-6329	1.5884213	8.59E-05
miR-326-3p	-1.1121066	9.61E-05
miR-34b-5p	1.61261524	0.000101199

Table 3 (continued)

Table 3 (continued)

miRNA	log ₂ -ratio (SCI-3/NC)	P value
miR-298-5p	1.45716953	0.000101971
miR-466b-4-3p	2.93009212	0.000107491
miR-466b-2-3p	2.93009212	0.000107491
miR-212-3p	1.75667346	0.000112073
miR-324-3p	-1.0864263	0.000122576
miR-20a-5p	1.28625132	0.000125546
miR-1249	-1.2134585	0.000135676
miR-9a-3p	-1.7243301	0.000150736
miR-345-5p	-1.0130189	0.00018066
miR-3099	-4.9919378	0.000189656
miR-133a-3p	-1.1249025	0.000216883
miR-130b-3p	2.16623648	0.000219139
miR-106b-5p	1.09029431	0.000274774
miR-672-5p	-1.0029872	0.000296051
miR-338-3p	-1.1388944	0.000309787
miR-17-5p	1.13609523	0.000417046
miR-3577	-1.3768138	0.000428649
miR-148a-5p	1.09743129	0.00044269
miR-511-3p	1.35189925	0.000479029
miR-196a-5p	-1.1142367	0.000655131
miR-708-3p	-1.2495066	0.000776355
miR-323-3p	-1.0204913	0.000807575
miR-540-3p	-1.1112974	0.000817585
miR-296-3p	1.93252131	0.00095342

compared with the NC group, 96, 28, and 51 miRs were downregulated in the rat bladders of SCI-1, SCI-2, and SCI-3 groups, respectively, and 133, 49, and 76 miRs were upregulated in the rat bladders of SCI-1, SCI-2, and SCI-3 groups, respectively. Specifically, miR-21-5p was the most significantly upregulated miR in all SCI groups. In addition, 121 miRs (SCI-1 vs. SCI-2), 98 miRs (SCI-1 vs. SCI-3), and 26 miRs (SCI-2 vs. SCI-3) were of significantly different expression. Moreover, 206 new miRs were identified in the bladder. Furthermore, a large set of genes implicated in essential signaling pathways were targeted by these miRs, including PI3K-Akt, MAPK, Rap1, and cGMP-PKG

Table 4 Eighty-one significantly down-regulated and 40 significantly up-regulated miRNAs in SCI-2 group compared to SCI-1 group

miRNA	log ₂ -ratio (SCI-2/SCI-1)	P value
miR-133a-3p	2.608263788	2.62E-43
miR-411-5p	-2.74522037	3.11E-35
miR-134-5p	-3.01646037	2.01E-34
miR-133b-3p	2.241527254	3.13E-32
miR-540-3p	-3.4576132	1.95E-27
miR-370-3p	-3.35185426	1.19E-23
miR-434-5p	-3.26188865	4.77E-23
miR-770-3p	-3.12840943	2.15E-22
miR-379-5p	-2.65131382	1.68E-21
miR-495	-3.4738593	1.98E-21
miR-410-3p	-2.32240022	7.25E-21
miR-143-5p	1.532807273	1.56E-19
miR-485-3p	-2.33658978	2.64E-19
miR-376b-3p	-3.79903309	4.43E-19
miR-341	-2.6472862	2.49E-18
miR-145-5p	2.729755793	5.27E-18
miR-320-3p	1.359090737	1.18E-17
miR-543-3p	-3.25484939	2.27E-17
miR-127-3p	-1.9670069	1.46E-16
miR-490-3p	1.567095484	2.44E-16
miR-29b-5p	2.31974577	7.07E-16
miR-125a-5p	1.373690239	2.97E-15
miR-300-3p	-2.21735369	3.96E-15
miR-541-5p	-2.31005283	8.60E-15
miR-380-3p	-3.43639219	9.76E-14
miR-296-3p	-3.36779258	1.25E-13
miR-205	1.462348678	1.99E-13
miR-493-5p	-2.55161665	2.86E-13
miR-1b	1.191285776	3.63E-13
miR-375-3p	1.470598973	3.82E-13
miR-409a-3p	-2.22414306	4.39E-13
miR-493-3p	-2.54745748	6.05E-13
miR-382-3p	-3.11323256	9.03E-13

Table 4 (continued)

Table 4 (continued)

miRNA	log ₂ -ratio (SCI-2/SCI-1)	P value
miR-181a-5p	1.056129411	9.66E-13
miR-411-3p	-2.61227376	2.57E-12
miR-369-5p	-2.12220497	3.62E-12
miR-494-3p	-2.10745377	1.32E-11
miR-130b-5p	-1.26694073	1.65E-11
miR-299b-3p	-2.11524277	1.70E-11
miR-382-5p	-1.61074807	3.04E-11
miR-299a-3p	-2.01331537	6.99E-11
miR-758-3p	-2.94825106	9.10E-11
miR-218a-5p	-1.25014301	1.14E-10
miR-378a-5p	1.109953116	1.35E-10
miR-132-5p	-1.73490045	1.45E-10
miR-455-5p	-1.31786364	1.64E-10
miR-1247-3p	-2.57037848	2.97E-10
miR-379-3p	-2.26202154	3.01E-10
miR-365-3p	1.643485681	3.40E-10
miR-1-3p	1.413388204	3.92E-10
miR-1193-3p	-2.17397441	4.59E-10
miR-664-3p	1.389462332	4.90E-10
miR-127-5p	-1.78617864	7.25E-10
miR-452-5p	-2.21588601	1.13E-09
miR-139-5p	1.337379266	1.27E-09
miR-434-3p	-1.30726196	2.12E-09
miR-337-5p	-1.9546922	2.16E-09
miR-466c-5p	-1.74885079	3.20E-09
miR-330-3p	1.378312119	6.07E-09
miR-496-3p	-1.86126645	9.30E-09
miR-133a-5p	1.515887194	9.33E-09
miR-485-5p	-1.309451	1.38E-08
miR-431	-2.07956874	2.03E-08
miR-126a-3p	-1.13484835	3.27E-08
miR-1249	1.2596351	4.17E-08
miR-409a-5p	-1.7399784	6.30E-08
miR-186-5p	1.016668658	7.25E-08

Table 4 (continued)

Table 4 (continued)

miRNA	log ₂ -ratio (SCI-2/SCI-1)	P value
miR-1843a-3p	1.250062543	1.08E-07
miR-212-5p	-1.36063182	1.42E-07
miR-433-3p	-1.5483857	1.70E-07
miR-323-3p	-1.16570373	1.85E-07
miR-99a-3p	2.133335482	1.98E-07
let-7c-1-3p	-1.58017681	2.27E-07
let-7c-2-3p	-1.03717891	2.39E-07
let-7a-1-3p	-1.03717891	2.39E-07
let-7d-3p	1.080665154	2.61E-07
miR-26b-3p	1.232968381	2.66E-07
miR-466b-5p	-1.49395071	2.73E-07
miR-212-3p	-1.5850046	2.82E-07
miR-6331	-1.60680229	3.32E-07
miR-150-5p	1.366309319	3.50E-07
miR-487b-3p	-1.28578195	4.17E-07
miR-708-5p	1.49100303	4.23E-07
miR-665	-3.21581941	5.22E-07
miR-322-3p	-1.17394689	5.48E-07
miR-29c-5p	1.287011985	5.51E-07
miR-103-3p	1.048341116	6.97E-07
miR-673-3p	-2.71045179	1.53E-06
miR-505-3p	1.00770467	1.58E-06
miR-667-3p	-1.46537091	1.80E-06
miR-298-5p	-1.74380033	2.26E-06
miR-139-3p	1.212784082	3.34E-06
miR-346	2.681838145	4.38E-06
miR-154-5p	-1.25813496	8.95E-06
miR-369-3p	-2.1952968	9.03E-06
miR-376b-5p	-1.76232448	1.15E-05
miR-6329	-1.51973384	1.63E-05
miR-342-3p	1.532839319	1.75E-05
miR-466b-3p	-1.55817849	1.94E-05
miR-148a-3p	-1.08230586	2.31E-05
miR-1188-5p	-5.54436782	2.42E-05
miR-148a-5p	-1.14139035	3.15E-05

Table 4 (continued)

Table 4 (continued)

miRNA	log ₂ -ratio (SCI-2/SCI-1)	P value
miR-667-5p	-3.63119254	4.30E-05
miR-329-3p	-1.27792595	4.34E-05
miR-383-5p	1.139922737	5.92E-05
miR-3473	-1.06517431	5.97E-05
miR-136-3p	-1.84129683	8.01E-05
miR-412-5p	-1.6696497	0.00011838
miR-138-5p	1.158249483	0.00012067
miR-190a-5p	1.795778971	0.00014354
miR-673-5p	-1.44773878	0.00022481
miR-541-3p	-4.82904003	0.00022815
miR-136-5p	-1.98858235	0.00026216
miR-376a-5p	-1.54201787	0.00035526
miR-324-5p	1.513136796	0.00038516
miR-210-5p	1.351344165	0.0004134
miR-412-3p	-2.47723181	0.00051183
miR-329-5p	-1.05001232	0.00055935
miR-129-1-3p	1.190742769	0.00072475
miR-144-5p	-3.13263127	0.00084192
miR-193b-3p	1.001305355	0.00088215

signaling pathways, along with tight junction and metabolic pathways.

These essential signaling pathways have been previously implicated in bladder dysfunction. miR - 139 - 5p may inhibit epithelial-mesenchymal transition (EMT) and fibrosis by targeting the lysophosphatidic acid receptor 4 via the PI3K-Akt signaling pathway (8). Also, the activation of the PI3K-Akt signaling pathway may play a pivotal part in bladder ischemia, which might be a mediating variable in the development of detrusor overactivity or fibrosis (9). Furthermore, collagen expression and bladder hypertrophy were regulated by nerve growth factor through the Akt and MAPK pathways (10). In addition, activation of the cGMP-PKG signaling pathway may result in bladder relaxation or reduce phasic contractions in rat bladder strips (11,12). Whether the signaling pathways targeted by these miRs can exhibit these functions mentioned above *in vivo* will be explored in further studies.

Among these miRNAs, miR-139-5p was the most

Table 5 Sixty-five significantly down-regulated and 33 significantly up-regulated miRNAs in SCI-3 group compared to SCI-1 group

miRNA	log ₂ -ratio (SCI-3/SCI-1)	P value
miR-146a-5p	1.878042516	8.93E-37
miR-540-3p	-3.751734752	3.73E-27
miR-543-3p	-2.958431994	5.83E-27
miR-134-5p	-2.624393149	1.57E-19
miR-494-3p	-2.973587278	3.83E-19
miR-370-3p	-2.664379953	5.38E-17
miR-493-5p	-2.492148624	3.97E-15
miR-770-3p	-2.780437641	5.27E-15
miR-485-3p	-2.311086657	5.48E-15
miR-1193-3p	-2.704554006	8.41E-15
miR-495	-2.743261007	1.31E-14
miR-382-3p	-2.513966714	1.33E-14
miR-541-5p	-2.328672663	6.51E-14
miR-493-3p	-2.435884804	3.51E-13
miR-337-5p	-2.312570335	3.85E-13
miR-341	-2.434201752	5.56E-12
miR-376b-3p	-3.111137592	8.89E-12
miR-379-3p	-2.551934532	1.65E-11
miR-411-3p	-2.323997165	2.01E-11
miR-1-3p	1.659870986	2.07E-11
miR-410-3p	-2.054195029	2.39E-11
miR-147	2.286330615	4.25E-11
miR-127-3p	-1.978595216	5.04E-11
miR-434-5p	-2.322200603	9.57E-11
miR-411-5p	-2.291934623	1.21E-10
miR-409a-3p	-2.018814703	1.56E-10
miR-450b-5p	1.327335478	3.50E-10
miR-379-5p	-2.078289512	4.19E-10
miR-503-5p	1.407318699	5.38E-10
miR-380-3p	-2.735493487	1.11E-09
miR-299b-3p	-2.132435754	1.41E-09
miR-296-3p	-2.112403772	1.63E-09
miR-378a-3p	1.274040685	2.90E-09
miR-431	-2.279766651	3.67E-09

Table 5 (continued)

Table 5 (continued)

miRNA	log ₂ -ratio (SCI-3/SCI-1)	P value
miR-299a-3p	-2.028869086	3.76E-09
miR-298-5p	-1.678094702	4.48E-09
miR-139-5p	1.338557747	4.94E-09
miR-667-3p	-2.121081559	5.85E-09
miR-433-3p	-2.032443133	6.54E-09
miR-378b	1.330449134	6.58E-09
miR-450a-5p	1.213624392	9.28E-09
miR-30a-5p	1.009740011	1.41E-08
miR-673-5p	-2.582751768	1.48E-08
miR-200b-3p	1.281104992	1.85E-08
miR-369-3p	-3.511118964	2.17E-08
miR-150-5p	1.584894696	2.77E-08
miR-199a-3p	-1.008269662	3.79E-08
miR-200a-5p	1.37962997	4.43E-08
miR-29c-5p	1.286799126	1.02E-07
miR-142-3p	1.494463185	1.66E-07
miR-409a-5p	-1.857335578	1.79E-07
miR-452-5p	-1.78484171	3.14E-07
miR-758-3p	-2.049501653	3.20E-07
miR-143-5p	1.211529311	3.25E-07
miR-295-3p	4.385869068	3.26E-07
miR-382-5p	-1.717644065	4.18E-07
miR-133a-3p	1.444110968	4.65E-07
miR-31a-5p	-1.069559874	5.19E-07
miR-665	-3.289848451	5.46E-07
miR-369-5p	-1.84198704	6.33E-07
miR-211-5p	1.487439804	7.04E-07
miR-132-5p	-1.154477693	8.31E-07
miR-154-5p	-1.727332132	1.23E-06
miR-296-5p	-1.66198682	1.49E-06
miR-434-3p	-1.722258416	1.62E-06
miR-323-3p	-1.508148562	1.69E-06

Table 5 (continued)

Table 5 (continued)

miRNA	log ₂ -ratio (SCI-3/SCI-1)	P value
miR-29b-5p	1.566473951	3.92E-06
miR-214-3p	-1.03183723	4.58E-06
miR-322-5p	1.228178334	5.88E-06
miR-1247-3p	-1.723138821	6.53E-06
miR-429	1.203161356	7.13E-06
miR-320-3p	1.006670327	9.97E-06
miR-490-3p	1.313994447	1.12E-05
miR-224-5p	-1.195347596	1.39E-05
miR-300-3p	-1.740405801	1.58E-05
miR-496-3p	-1.716315672	1.72E-05
miR-292-5p	3.161923228	2.09E-05
miR-127-5p	-1.498705818	2.52E-05
miR-217-5p	1.067552536	2.84E-05
miR-3068-5p	1.103827166	3.16E-05
miR-133b-3p	1.260733165	4.41E-05
miR-145-5p	2.10010759	4.44E-05
miR-212-3p	-1.559406326	6.83E-05
miR-142-5p	1.693814748	8.30E-05
miR-329-3p	-1.516830797	9.78E-05
miR-1247-5p	-1.156715953	9.89E-05
miR-376a-5p	-1.849609395	0.000106477
miR-487b-3p	-1.416933909	0.000183408
miR-667-5p	-2.942414133	0.000184457
miR-673-3p	-2.263333428	0.000245072
miR-342-3p	1.008002812	0.000290457
miR-485-5p	-1.287206338	0.000305075
miR-138-5p	1.088542695	0.000349689
miR-376b-5p	-1.734005747	0.000448709
miR-134-3p	-2.765506432	0.000510032
miR-541-3p	-4.093660794	0.000697524
miR-494-5p	-2.583117839	0.000707698
miR-7a-5p	1.096870146	0.000976127

Table 6 Five significantly down-regulated and 21 significantly up-regulated miRNAs in SCI-3 group compared to SCI-2 group

miRNA	log ₂ -ratio (SCI-3/SCI-2)	P value
miR-146a-5p	1.430251032	5.24E-17
miR-503-5p	2.311893164	7.21E-16
miR-450a-5p	1.769066039	4.18E-13
miR-147	3.020864346	4.29E-13
miR-21-5p	1.035558921	4.19E-12
miR-450b-5p	1.979394682	1.61E-10
miR-375-3p	-1.83606718	1.39E-09
miR-142-5p	2.537262571	1.26E-08
miR-31a-5p	-1.38115753	5.06E-08
miR-322-5p	1.495334178	5.89E-08
miR-542-3p	1.387065444	1.23E-06
miR-200a-5p	1.437411924	1.65E-06
miR-363-3p	1.433656424	8.33E-06
miR-295-3p	4.835196043	2.03E-05
miR-133a-3p	-1.17375178	2.21E-05
miR-146b-3p	1.718251812	2.93E-05
miR-292-5p	3.632736184	6.28E-05
miR-211-5p	1.401188165	7.22E-05
miR-6329	1.792658779	7.88E-05
miR-130b-5p	1.515981749	0.000101517
miR-148a-5p	1.259651293	0.000129725
miR-451-5p	2.563264678	0.000214476
miR-210-5p	-1.8865576	0.000354357
miR-466b-5p	1.246519093	0.000387425
miR-146b-5p	2.000586182	0.000834152
miR-3102	-1.51339849	0.000890494

significantly downregulated miR in the SCI-1 group. Though its level was inclined to follow an increasing trend within 2 weeks after spinal cord injury and thereafter remained stable, its level was also significantly lower than that of the NC group. Specifically, compared with NC group, the expression of miR-139-5p was downregulated by 4.22-fold in the SCI-1 group, while its level was upregulated by 1.98- and 1.94-fold in the SCI-2 and SCI-3 groups compared to the SCI-1 group, with no statistical difference between the SCI-2 and SCI-3 groups. These results were

confirmed by the qRT-PCR findings.

Recently, Firat *et al.* also reported that miR - 139 - 5p was significantly downregulated in OAB patient plasma (7). Rho-associated coiled-coil-containing protein kinase 2 (ROCK2) was identified as a direct target of miR-139-5p and was effective in the ROCK2/myosin-light chain (MLC) and cholinergic pathway. It was proven that contractions of the bladder detrusor in humans are primarily mediated by M₃ receptors and depend on inhibiting MLC phosphatase by the activation of ROCK, leading to increased sensitivity to Ca²⁺ (13). Previous data have suggested that the inhibition of ROCK could ameliorate or reverse detrusor overactivity (14,15). By considering the previous data showing that upregulated RhoA/ROCK signaling is one of the factors that contribute to the development of detrusor overactivity, we speculate that a reduced level of miR - 139 - 5p may upregulate the expression of ROCK2, resulting in or aggravating detrusor overactivity. Moreover, miR - 139 - 5p was found to inhibit EMT and fibrosis by targeting lysophosphatidic acid receptor 4 via the PI3K-Akt signaling pathway (8).

In addition, miR-21-5p was the most significantly upregulated miR in all SCI groups. Indeed, miR-21-5p has been reported to act as an oncogene through inhibiting cellular apoptosis by targeting tumor suppressor genes (16). However, it should be noted that the overexpression of miR-21-5p abnormally activates transforming growth factor-β1 (TGF-β1) and Hedgehog signaling pathways, promoting tumor invasion by the induction of EMT. It is widely accepted that, TGF-β1 signaling pathway plays a pivotal role in EMT and fibrogenesis. Recently, the upregulated expression of miR-21-5p was reported to be involved in renal, myocardial, pulmonary, and peritendinous fibrosis and may serve as an alternative target to directly inhibit this fibrosis (17-20). Further research indicates that miR-21-5p overexpression may enhance TGF-β1-induced EMT by inhibiting Smad7 (21). Moreover, proliferation, migration, and pro-fibrotic activities of fibroblasts were found to be promoted by miR-21-5p through reducing Smad7 expression (18). More specifically, the increase of intracellular miR-21-5p induced fibroblasts differentiation into myofibroblasts and the overexpression of extracellular matrix (ECM) and fibrogenic markers. Moreover, tissue inhibitor of metalloproteinases (TIMPs) which was implicated in collagen synthesis and accumulation during fibrosis were also targeted by miR-21-5p (22).

Importantly, previous study suggests that miR-21-5p is upregulated by TGF-β1 via activation of Smad3 rather than




Figure 1 Signaling pathways targeted by miR-139-5p, miR-21-5p, miR-149-5p, miR-146a-5p, miR-134-5p, miR-132-3p, and miR-132-5p. Red color indicates the upregulated miRNAs in the SCI-1 group compared to the NC group, while green indicates those that were downregulated.

Smad2 (23). In a normal state, Smad-3 activation can induce the expression of Smad7, which forms a negative feedback mechanism (24). Nevertheless, in pathological situations, the expression of Smad7 was found to be suppressed, and the negative feedback damaged, which may be due to the upregulated expression of miR-21-5p. In contrast, the conditional knockout of Smad2 could enhance miR-21-5p expression (23). Further research is needed to explore the mechanisms underlying the interactions between miR-21-5p and the TGF- β 1 signaling pathway. Also, bladder fibrosis after spinal cord injury may bear responsibility for the high intravesical pressures, low bladder compliance, bladder wall

stiffness and vesicoureteral reflux (25). Currently, however, there is no effective method for preventing bladder fibrosis. Therefore, it is also of great significance to investigate the functional role of miR-21-5p in bladder fibrosis after spinal cord injury.

The differentially expressed miRNAs between SCI groups were also investigated in this study and showed distinct patterns of expression over time. Specifically, we found that miR-146a-5p was upregulated by 5.48-, 2.51-, and 3.46-fold in the SCI-3 group compared to the NC, SCI-1, and SCI-2 groups respectively, while miR-146a-5p was upregulated by 2.19-fold in the SCI-1 group compared to




Figure 2 Genes targeted by miR-139-5p, miR-21-5p, miR-149-5p, miR-146a-5p, miR-134-5p, miR-132-3p, and miR-132-5p. Red color indicates the upregulated miRNAs in the SCI-1 group compared to the NC group, while green indicates those that were downregulated.

the NC group. In addition, miR-134-5p was significantly upregulated in the SCI-1 group compared to the NC, SCI-2, and SCI-3 groups as revealed by NGS and qRT-PCR. Other studies have found that miR-146a-5p could attenuate hepatic fibrosis by negatively regulating the PTPRA-SRC signaling pathway or inhibiting the profibrogenic effects of TGF-β1 and lipopolysaccharide (26,27). Furthermore,

transcription factor twist1 directly targeted by miR-134-5p was also implicated in EMT and fibroblast activation and tissue fibrosis in a TGF-β/Smad3-dependent manner (28).

Suprasacral spinal cord injury can abruptly disrupt intraspinal pathways and result in the “spinal shock” phase, during which the bladder is often atonic and areflexic and typically present with overflow incontinence (29).




Figure 3 The level of miR-139-5p, miR-21-5p, miR-149-5p, miR-146a-5p, and miR-134-5p between different groups by qRT-PCR. Data are presented as the mean \pm SD. *, $P < 0.05$ vs. NC group; #, $P < 0.05$ vs. SCI-1 group. NC, normal control; SCI-1, spinal cord-injured-1; SCI-2, spinal cord-injured-2; SCI-3, spinal cord-injured-3.

However, the relative concentration of collagen in rat bladders was reported to be significantly decreased in the first 10 days after spinal cord injury (30), which may be in agreement with the expression of miR-134-5p to a certain extent. Therefore, it is reasonable to presume that miR-134-5p might play a role in it. After spinal shock, hypermechanosensitive C-fiber bladder wall afferents were activated gradually and urodynamic findings were mainly characterized by detrusor overactivity or detrusor-sphincter dyssynergia. miR-146a-5p may be involved in this stage of NB due to that it was significantly upregulated in the SCI-3 group compared to the SCI-1 group. In summary, it will be very interesting and meaningful to investigate the relationship between the dynamic change of these differentially expressed miRs and the different stages of NB.

In this study, we investigated the differentially expressed miRs between groups by NGS and qRT-PCR. Furthermore, 206 new miRs were identified in the bladder, and a large set of genes implicated in essential signaling pathways targeted by these miRs were identified. Nevertheless, this study also has some limitations. Firstly, the interactions between miRs and mRNA were not explored. Thus, further experimental studies are needed to verify the proposed interactions and

their roles in NB in the future. Secondly, bladder tissues collected 8 weeks or more after spinal cord transection may be required to investigate those miRs that might function at that time. For example, Wang *et al.* reported that there was no significant difference in the expression of bladder miR-1949 between rats without spinal cord injury and those collected at 3 months following spinal cord injury, while it was significantly increased after the third month (31). Thirdly, more samples or human bladder tissue should be analyzed to confirm our results.

Conclusions

Several miRs were differentially expressed in the SCI rat NB, and may potentially serve as new molecular targets for NB.

Acknowledgments

ZHS would like to thank Miss Xiaolin Liu for her valuable understanding and assistance.

Funding: This work was supported by the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (No. ZYLX201801).

Footnote

Reporting Checklist: The authors have completed the ARRIVE reporting checklist. Available at <http://dx.doi.org/10.21037/tau-20-415>

Data Sharing Statement: Available at <http://dx.doi.org/10.21037/tau-20-415>

Peer Review File: Available at <http://dx.doi.org/10.21037/tau-20-415>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/tau-20-415>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All experimental procedures were implemented in compliance with the National Institute of Health Guidelines for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Xuanwu Hospital Capital Medical University (No. 20190128).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Przydacz M, Chlosta P, Corcos J. Recommendations for urological follow-up of patients with neurogenic bladder secondary to spinal cord injury. *Int Urol Nephrol* 2018;50:1005-16.
- Shang Z, Jia C, Yan H, et al. Injecting RNA interference lentiviruses targeting the muscarinic 3 receptor gene into the bladder wall inhibits neurogenic detrusor overactivity in rats with spinal cord injury. *Neurourol Urodyn* 2019;38:615-24.
- Hu HZ, Granger N, Jeffery ND. Pathophysiology, Clinical Importance, and Management of Neurogenic Lower Urinary Tract Dysfunction Caused by Suprasacral Spinal Cord Injury. *J Vet Intern Med* 2016;30:1575-88.
- Oliveira R, Coelho A, Franquinho F, et al. Effects of early intravesical administration of resiniferatoxin to spinal cord-injured rats in neurogenic detrusor overactivity. *Neurourol Urodyn* 2019;38:1540-50.
- Hamid R, Averbeck MA, Chiang H, et al. Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. *World J Urol* 2018;36:1517-27.
- Chermansky CJ, Kadow BT, Kashyap M, et al. MicroRNAs as potential biomarkers to predict the risk of urinary retention following intradetrusor onabotulinumtoxin-A injection. *Neurourol Urodyn* 2018;37:99-105.
- Firat E, Aybek Z, Akgun S, et al. Exploring biomarkers in the overactive bladder: Alterations in miRNA levels of a panel of genes in patients with OAB. *Neurourol Urodyn* 2019;38:1571-8.
- Jiang C, Tong Z, Fang WL, et al. MicroRNA-139-5p inhibits epithelial-mesenchymal transition and fibrosis in post-menopausal women with interstitial cystitis by targeting LPAR4 via the PI3K/Akt signaling pathway. *J Cell Biochem* 2018;119:6429-41.
- Yang JH, Siroky M, Yalla S, et al. Mitochondrial stress and activation of PI3K and Akt survival pathway in bladder ischemia. *Res Rep Urol* 2017;9:93-100.
- Chung CW, Zhang QL, Qiao LY. Endogenous nerve growth factor regulates collagen expression and bladder hypertrophy through Akt and MAPK pathways during cystitis. *J Biol Chem* 2010;285:4206-12.
- d'Emmanuele di Villa Bianca R, Mitidieri E, Fusco F, et al. Urothelium muscarinic activation phosphorylates CBS(Ser227) via cGMP/PKG pathway causing human bladder relaxation through H2S production. *Sci Rep* 2016;6:31491.
- Artim DE, Kullmann FA, Daugherty SL, et al. Activation of the nitric oxide-cGMP pathway reduces phasic contractions in neonatal rat bladder strips via protein kinase G. *Am J Physiol Renal Physiol* 2009;297:F333-40.
- Wróbel A, Rechberger T. The Influence of Maxacalcitol, Vitamin D3 Analog, on Detrusor Overactivity in Conscious Rats. *Urology* 2016;93:224.e7-224.e15.
- Wróbel A, Serefko A, Rechberger E, et al. Inhibition of Rho kinase by GSK 269962 reverses both corticosterone-induced detrusor overactivity and depression-like behaviour in rats. *Eur J Pharmacol* 2018;837:127-36.
- Wróbel A, Rechberger T. The influence of Rho-kinase inhibition on acetic acid-induced detrusor overactivity.

- Neurourol Urodyn 2017;36:263-70.
16. Ghorbanmehr N, Gharbi S, Korsching E, et al. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer. *Prostate* 2019;79:88-95.
 17. Nonaka CKV, Macêdo CT, Cavalcante BRR, et al. Circulating miRNAs as Potential Biomarkers Associated with Cardiac Remodeling and Fibrosis in Chagas Disease Cardiomyopathy. *Int J Mol Sci* 2019;20:4064.
 18. Cui H, He Y, Chen S, et al. Macrophage-Derived miRNA-Containing Exosomes Induce Peritendinous Fibrosis after Tendon Injury through the miR-21-5p/Smad7 Pathway. *Mol Ther Nucleic Acids* 2019;14:114-30.
 19. Wang J, He F, Chen L, et al. Resveratrol inhibits pulmonary fibrosis by regulating miR-21 through MAPK/AP-1 pathways. *Biomed Pharmacother* 2018;105:37-44.
 20. Sun L, Xu T, Chen Y, et al. Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation. *Life Sci* 2019;232:116609.
 21. Wang JY, Gao YB, Zhang N, et al. miR-21 overexpression enhances TGF-beta1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. *Mol Cell Endocrinol* 2014;392:163-72.
 22. Almalki SG, Agrawal DK. Effects of matrix metalloproteinases on the fate of mesenchymal stem cells. *Stem Cell Res Ther* 2016;7:129.
 23. Zhong X, Chung AC, Chen HY, et al. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. *J Am Soc Nephrol* 2011;22:1668-81.
 24. Lan HY. Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. *Int J Biol Sci* 2011;7:1056-67.
 25. Fry CH, Kitney DG, Paniker J, et al. Fibrosis and the bladder, implications for function ICI-RS 2017. *Neurourol Urodyn* 2018;37:S7-S12.
 26. Yuan BY, Chen YH, Wu ZF, et al. MicroRNA-146a-5p Attenuates Fibrosis-related Molecules in Irradiated and TGF-beta1-Treated Human Hepatic Stellate Cells by Regulating PTPRA-SRC Signaling. *Radiat Res* 2019;192:621-9.
 27. Zou Y, Cai Y, Lu D, et al. MicroRNA-146a-5p attenuates liver fibrosis by suppressing profibrogenic effects of TGFbeta1 and lipopolysaccharide. *Cell Signal* 2017;39:1-8.
 28. Palumbo-Zerr K, Soare A, Zerr P, et al. Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis. *Ann Rheum Dis* 2017;76:244-51.
 29. Shi P, Zhao X, Wang J, et al. Effects of acute sacral neuromodulation on bladder reflex in complete spinal cord injury rats. *Neuromodulation* 2013;16:583-9; discussion 589.
 30. Nagatomi J, Gloeckner DC, Chancellor MB, et al. Changes in the biaxial viscoelastic response of the urinary bladder following spinal cord injury. *Ann Biomed Eng* 2004;32:1409-19.
 31. Wang T, Liu Y, Yuan W, et al. Identification of microRNAome in rat bladder reveals miR-1949 as a potential inducer of bladder cancer following spinal cord injury. *Mol Med Rep* 2015;12:2849-57.

Cite this article as: Shang Z, Ou T, Xu J, Yan H, Cui B, Wang Q, Wu J, Jia C, Cui X, Li J. MicroRNA expression profile in the spinal cord injured rat neurogenic bladder by next-generation sequencing. *Transl Androl Urol* 2020;9(4):1585-1602. doi: 10.21037/tau-20-415

Table S1 Two hundred and six new miRNAs identified in the bladder

miRNA_id	Mature sequence
chr9_13944	augagcguccuauccacaagcu
chr7_10857	cacagucuauguccuuggaagc
chr9_13550	uggcuaucuggaguccucugga
chr5_8282	cacagcgaggcugggacacuggcgu
chr18_22514	cacagcgaggcugggacacuggcgu
chr3_5314	acaagcuaaagguuggggacu
chr15_19802	ucaagcgaguccaggcuagccuug
chr5_8901	uuggaaggacuugugaaggugu
chr7_11359	aucucgguggaaccucca
chrX_24487	aucucgguggaaccucca
chr3_5244	aucucgguggaaccucca
chr17_21861	uugucuguguauguccaugugu
chr13_18372	uucccgcccaaugcacca
chr10_14593	uaggauuugcugaaggagg
chr16_20779	ugggcgccuccgaugugguuc
chr17_21589	cuuggcaccugguaagcacuca
chr1_1510	caggagggcgggcggggg
chr6_9331	caggagggcgggcggggg
chr11_16694	aagccaacucuccagauucga
chr6_10216	ucagacuucugcuccaccacga
chrX_23975	ucauccaccuuguguccugcagc
chr6_9812	aggaguuugggguuuagcu
chr17_21639	ucggcgccccacacugagcuu
chr1_603	cauaaguuagagagucugua
chr3_5685	cauguuccacacucucacaga
chr2_3705	uuggccaggugguugucugaca
chr1_361	caccugucccauucucuaaga
chr1_340	uugggaacggggugucucuggga
chr16_20784	cggaccuagugaaccagagugc
chr17_21860	acacacuaaacaacacacgca
chrX_24300	acuaccacuaucacucuccacagc
chr12_17242	acuugcauguaacacuuuccuga
chr12_17244	acuugcauguaacacuuuccuga
chr2_4354	uccgacucucugagcucugccagg
chrX_24426	cuggauuggcugggcccc
chr10_15831	ugcagacuccucuggcugaugug
chr2_3993	uccuacuaugugaacagcgcau
chr10_16212	caucuccaccuugucucccgca
chr12_17361	ugaccuaguccuucucccaag
chr4_6449	ucuccgccaccuccaccgagc
chr5_8531	aaagccuccgagucacuggau
chr7_11153	ggugacaguuagcugauguugc
chr3_5493	auguuuccugacuauuccugg
chr8_12585	cucccgccuguaaaccucccau
chr20_23557	cggaggaguggucucccgccg
chr7_11744	agcugacacucuccucacagg
chr4_6026	aagcccccggaaacacucucc
chrX_24141	uagucucucucucucucugca
chr12_17462	ucccugucggggcccau
chr2_4466	uucggcugcauuucugguuu
chr5_8280	uugacucucuggggccagcag
chr1_1381	ucacucugccuuucucccaga
chr1_1382	ucacucugccuuucucccaga
chr7_10721	cagcuggcucucuuuccuuu
chr18_22438	aagcccccucacucucccaac
chr1_2525	aguggcuauagggcaccuggu
chr1_2511	ucaagggcacaggagcugau
chr1_2513	ucaagggcacaggagcugau
chr17_21586	uuaggacucugguacucuuugg
chr10_14618	ugcccgccuuccucccaggg
chr7_11083	ggggggcuagaggucauggu
chr14_18974	ucugcgcgagcguuugcucucu
chr1_328	auggaggagagcaggagagugu
chr1_437	uaggguugucuguguccucc
chr10_15933	ugagggggccucagaccgagcuu
chr8_12972	uugguaccuguuuccuguu
chrX_24393	uggggcgaggccggaucuauggg
chr1_916	cucuggcaccgguuaugggacu
chr10_15921	ggucugccugugggccuccg
chr16_20914	uccucuguaagagcagucagau
chr18_22500	gugguguguuaguauucuuuc
chr9_13419	cagcccccucucugcucuuu
chrX_24406	ugacuauccagagaaccuuuga
chr11_16570	ccagguccacucugcugagcacu
chr6_9744	uguaagacuauuggaacguagg
chr12_17313	caagcucccuacagcgcgccagc
chr11_16624	uuccuucuguaauugugugcu
chr20_23743	cuacugagccacauuccccagcc
chr12_17745	cagaaccucgucuccgacauga
chr7_11689	agcugugcugucugucuauguu
chrX_24231	aagacugugggagggcacau
chr5_8046	acacagaggaggagcugcauu
chr5_8194	uugucuccaccuagcccaguu
chr19_23144	ucucucuccuccucacugugg
chr18_22131	cuuguuuuucucuccuccaguu
chr14_19590	uuaggaccagacucuccgguuu
chr5_7648	ugaugucacugcacaugagggu
chr5_7647	ugaugucacugcacaugagggu
chr8_13325	aucugacuuaaggcugcugcucu
chr15_20213	aacggucguguguguccu
chr5_9184	uucucugugccccucucg
chr5_8577	uggguccagauuggucaaagcu
chr5_8578	uggguccagauuggucaaagcu
chr5_8169	guguaucugaccugucccagag
chr7_11752	ucugacucugccucccacaaga
chr5_8555	ugagugcuaggaaaccaacucu
chr3_5775	aggaguuugggguuuagcu
chr14_19318	ugauguguuuuauaccaguuug
chr17_21864	uacacaugcacacacacgca
chr19_23022	ugacccugugccccuccccac
chr4_6719	caacacugcaccggaagauugga
chr11_16638	cuaggcaggcagacuucaguu
chr3_4543	ucaagaguuucuaagucacugg
chr4_7462	ucauuccaccuuccucccaccag
chr4_7120	agacugugccggaagacugca
chr1_1573	ucccccccucccaccacacagg
chr7_11930	uugacucugcauuccucucaga
chr4_6414	uggggucuuugacuggaugugu
chr12_17840	cagaaccacagcuccucaguu
chr1_2083	acugggaccuggacaggaguuuu
chr18_22011	gaguuaggguuuuacugcugu
chr12_17307	ugucuccaucugcuccccacagg
chr1_862	uucggggugaggcggagucagc
chr4_7310	caaggacuuugagcuggagaga
chr5_9040	auaccggagcagagagagacacu
chr8_12723	uccacucuuauaccuagcacu
chr10_15695	uugggcccagccaaggacugg
chr9_13459	uguaugucuguauguaucaugu
chr1_1400	uguaugucuguauguaucaugu
chrX_24150	agggguuaggaguuuagcuc
chr2_3446	agggguuaggaguuuagcuc
chr2_3542	uugccugguuuagucucugcu
chr1_1619	ugacggagcagcaggaggagag
chr8_13260	uaucuccuuugagucuccacaca
chr9_14226	uauguccugucucuccuccagu
chr5_8174	agagacagagagcgcugcugcg
chr7_11241	ugacccgccccaccgagcagg
chr1_1100	cauuguaagggggaugagg
chr7_11944	ucagccacacucucccggu
chr20_23652	cacuagacugcucacucugcu
chr16_20541	ucugguuagucucucccagaga
chr17_21152	acucugggugucuguaacaagu
chr10_15514	ccuccggauccgggacccccga
chr3_5566	uaaagggggccaggcucugagc
chr3_5556	uaaagggggccaggcucugagc
chr1_2654	gacugggcccucucacucccu
chr17_21565	agcaggagagcuaacagagcuu
chr19_22791	ucacagaggggcugcugagc
chr2_3946	ugauuguuuuuuuguuugcu
chr3_5923	aacugggagaagauugggacacu
chr7_10924	uggcucacugaccucuaucuu
chr13_18744	cacugagcagcagacaugucuga
chr5_8132	aggccugucaggcaguuucugc
chr1_2215	aguugguuucaggauccucugau
chr10_15599	gcccggcucugccucugaccaggcc
chr5_8778	ugagguuaguuugcuguc
chr12_17541	cacuucagaggagagaggcugg
chr2_3411	uugcagauuggccugagcugag
chr17_21857	auguaaguguguauguaauugu
chr20_23190	ggacguccagacgcaacucug
chr1_1401	uggguacaguguaacuacagugu
chr1_1406	uggguacaguguaacuacagugu
chr1_1403	uggguacaguguaacuacagugu
chr1_1402	uggguacaguguaacuacagugu
chr6_9799	uggcgguuguggagcug
chr9_13614	aggcgcuuuuaacaguuuaggu
chr18_22253	acugcucucucuaaaggguuu
chr7_11818	agagguccacuguuuucucagu
chr10_16058	aggacugaggggcugagucucu
chr6_10344	ucuccugagccucugacugug
chr12_17299	ucuccuccuuaaccuccuag
chr1_2582	uucccaccuggcccaccuccag
chr13_18518	uuucucuuuuccaccuccug
chr6_9847	uucacagucucugucucccag
chr8_12680	gaagucugcugagagcuccagc
chr12_17880	uuggguuuguccucugcagag
chr11_17038	aggucuguggagaggucugcu
chr3_5989	ccaagccccuacuuucucagag
chr1_2094	ugagacucucugcugucuggc
chr14_18752	ugcggaaggguagcaugaguacc
chr1_1047	uuggccuccgucuccucccagg
chr13_18458	uuuggaacuccuccuccagggc
chr1_1914	uucccuccuucagucucccag
chr6_9478	cagucuaucugcucugucugcu
chr3_5408	ugcucuauggcugcguccag
chr7_10953	cgccuucuuuguccucagaga
chr9_13682	cagccucucacacaccagccu
chr4_7158	gugugcucagucacagucugcu
chr4_7157	gugugcucagucacagucugcu
chr4_7160	gugugcucagucacagucugcu
chr15_20159	ucucggcguccgacagug
chr9_13413	ugugaguuacacucuggcuga
chr17_21572	uuaccuuagccucugccccu
chr5_9125	ccuggcaaggaagguuucucugu
chr8_13188	cucgucuccgucuccgcuugac
chr18_22015	cugugguuccucugggugaug
chr10_15867	caccacagugguuuuggagcugg
chr14_19378	augaucucccucucucccaga
chr15_20240	uaucucuccgcccuccaccag
chr14_19708	ccucucugcucuaaggguagaga
chr6_9496	caccuccuccugccucuccuu
chr3_5852	cagccuggaccuacuuccuguu
chr7_10822	aggucuuuccauuuuugcuag
chr6_9471	augagacagcagcagcagau
chr9_14144	ucgguuugguuccuugucug
chr6_9316	cgagcuaucuccaaucuccug
chr10_14521	uucgcccgggguuuuccuugu
chr5_8036	ugaggauuacgaagaggauugu
chr6_10253	uaucuccuaccuagcucugug
chr9_14039	uguaucuuucuccaccggcu
chr20_23870	caccuccuccugcucucuauc
chr6_10184	agaagccuuaagucucucugacu
chr6_10183	agaagccuuaagucucucugacu
chr20_23751	accgugggacuaucuccu
chr12_17754	ucugagccuuaucucccagu
chr11_16818	uucugagacagucuccucucu